The significance of interleukin6 in the pathogenesis of anemia in patients with solid tumors and the possibility of therapeutic correction

The article presents the results of experimental and clinical studies in which the signi terleukin 6 on the development of anemia in patients with malignant tumors was studied. In terleukin 6 has been shown to stimulate the expression of the iron metabolism regulator, hepcidin protein by binding and subsequent activation of the signal converter and transcriptional activator 3. Results of studies show that interleukin stimulates tumor growth by inhibiting apoptosis and inducing angiogenesis of the tumor in the development and progression of cancer cachexia, and induces the synthesis of acute phase proteins. The results of experimental and clinical studies in which the possibility of using anti-IL-6 eceptor antibody for the purpose of correcting anemia caused by a malignant tumor is shown. It has been established that the appointment of anti-IL-6 receptor antibody in patients with cancer and anemia contributes to an increase in the level of hemoglobin, erythrocytes, as well as a decrease in the symptoms of the underlying disease. A similar effect was demonstrated after the use of this group of drugs in patients with cancer cachexia. Presented are the results of a comparative analysis of the concentration of interleukin 6 in cancer patients with anemia and without it. In patients with anemia, a higher interleukin-6 content was established (p function show_eabstract() { $('#eabstract1').hide(); $('#eabstract2').show(); $('#eabstract_expand').hide(); }